RecruitingPHASE1, PHASE2NCT04822337

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Studying Multiple myeloma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Wake Forest University Health Sciences
Principal Investigator
Shebli Atrash, MD, MS
Wake Forest University Health Sciences
Intervention
Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin(drug)
Enrollment
70 enrolled
Eligibility
18 years · All sexes
Timeline
2021 – 2032

Study locations (2)

Collaborators

Amgen · GlaxoSmithKline

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04822337 on ClinicalTrials.gov

Other trials for Multiple myeloma

Additional recruiting or active studies for the same condition.

See all trials for Multiple myeloma →

← Back to all trials